NCT06057948View on ClinicalTrials.gov

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

March 21, 2026

Study Completion Date

March 21, 2026

Conditions
NeuroblastomaHigh-risk NeuroblastomaMetastatic Neuroblastoma
Interventions
BIOLOGICAL

OPT-821 (QS-21)

Comprised of the immunological adjuvant OPT-821 (QS-21)

DIETARY_SUPPLEMENT

oral β-glucan

Participants will be randomized to receive this agent in two different schedules

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Consent only), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Consent Only), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Consent Only), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Consent Only), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER